Medistim ASA (OSL:MEDI)
229.00
+11.00 (5.05%)
Aug 1, 2025, 4:25 PM CET
Accolade Revenue
Medistim ASA had revenue of 181.55M NOK in the quarter ending March 31, 2025, with 35.70% growth. This brings the company's revenue in the last twelve months to 603.92M, up 14.89% year-over-year. In the year 2024, Medistim ASA had annual revenue of 556.16M with 6.73% growth.
Revenue (ttm)
603.92M
Revenue Growth
+14.89%
P/S Ratio
6.93
Revenue / Employee
3.92M
Employees
154
Market Cap
4.18B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 556.16M | 35.05M | 6.73% |
Dec 31, 2023 | 521.11M | 34.85M | 7.17% |
Dec 31, 2022 | 486.26M | 68.45M | 16.38% |
Dec 31, 2021 | 417.82M | 61.61M | 17.30% |
Dec 31, 2020 | 356.21M | -707.00K | -0.20% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Nordhealth AS | 545.88M |
Photocure ASA | 532.69M |
Vistin Pharma ASA | 440.66M |
Omda AS | 442.14M |
ArcticZymes Technologies ASA | 102.97M |
Gentian Diagnostics ASA | 163.38M |
Lytix Biopharma AS | 608.00K |
Nykode Therapeutics AS | 87.09M |
Medistim ASA News
- 5 months ago - Medistim ASA (STU:MD1) Q4 2024 Earnings Call Highlights: Record Sales and Strategic Innovations ... - GuruFocus
- 5 months ago - Q4 2024 Medistim ASA Earnings Call Transcript - GuruFocus
- 9 months ago - Medistim ASA (FRA:MD1) Q3 2024 Earnings Call Highlights: Strong Sales Growth in Americas Amid ... - GuruFocus
- 9 months ago - Q3 2024 Medistim ASA Earnings Call Transcript - GuruFocus